Profile

PurMinds NeuroPharma is a neuro-medicine development company pursuing breakthrough solutions for the treatment of neurological and psychiatric disorders. Its pre-clinical, small molecule program has developed a pipeline of novel, neuroprotective compounds that restore neuronal function and can address multiple clinical indications with significant unmet patient needs. PurMinds’ lead program involves non-hallucinogenic, cardiac safe and orally bioavailable neuroplastogens (serotonin 5-HT2A/C receptor partial agonists). These compounds have the potential to be a first-in-class approach to addressing multiple neurological and psychiatric disorders by promoting neuroplasticity without inducing hallucinations. Its secondary program focuses on highly selective inhibitors of histone deacetylase 6 (HDAC6i with broad therapeutic application.

PurMindsNeuroPharma logo

Website

purminds.com

Contact


Event details

Date: January 13 - 15, 2025

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

21 in total